胰高血糖素样肽-1受体激动剂使用对全髋与全膝关节置换术后临床结局的影响:346899例患者的系统综述与Meta分析
该系统综述与Meta分析纳入13项研究、共346899例患者,评估GLP-1RA对全髋和全膝关节置换术后结局的影响。GLP-1RA与TKA后90天假体周围感染风险降低(OR 0.75)及THA后90天翻修风险降低(OR 0.76)相关,并显著降低TKA和THA的90天再入院率。GLP-1RA与吸入或肺炎无显著关联,但与TKA后心肌梗死风险升高相关(OR 1.39)。
要点
- GLP-1RA与TKA后90天假体周围感染风险降低相关(OR 0.75,95%CI 0.57-1.00,P=0.047)。
- GLP-1RA与THA后90天翻修风险降低相关(OR 0.76,95%CI 0.59-0.98,P=0.034)。
- GLP-1RA与TKA和THA的90天再入院率显著降低相关,与吸入或肺炎无显著关联。
核心结论
- GLP-1RA的使用与THA和TKA后早期手术结局改善及资源利用减少相关。
- 这些发现提示GLP-1RA可能有益于优化接受全关节置换术的肥胖或糖尿病高危患者。
研究设计与样本
- 系统综述与Meta分析,检索PubMed(Medline)、Scopus(Embase、Medline和Compendex)及Cochrane数据库,检索时间从建库至2025年6月。
- 共纳入13项研究,包括119092例髋、227381例膝和426例髋或膝,在90天及1年和2年记录人口学、手术并发症、内科并发症、资源利用和翻修率。
- Meta分析采用随机效应模型。
主要发现
- GLP-1RA与TKA后90天假体周围感染风险降低相关(OR 0.75,95%CI 0.57-1.00,P=0.047)。
- GLP-1RA与THA后90天翻修风险降低相关(OR 0.76,95%CI 0.59-0.98,P=0.034)。
- GLP-1RA与TKA和THA的90天再入院率显著降低相关。
- GLP-1RA与吸入或肺炎无显著关联(OR 1.09,95%CI 0.71-1.67,P=0.70)。
- GLP-1RA与TKA后心肌梗死风险升高相关(OR 1.39,95%CI 1.05-1.85,P=0.02)。
关键数值与推荐
- TKA后90天假体周围感染:GLP-1RA组OR 0.75(95%CI 0.57-1.00,P=0.047)。
- THA后90天翻修:GLP-1RA组OR 0.76(95%CI 0.59-0.98,P=0.034)。
- 吸入或肺炎:GLP-1RA组OR 1.09(95%CI 0.71-1.67,P=0.70),无显著关联。
- TKA后心肌梗死:GLP-1RA组OR 1.39(95%CI 1.05-1.85,P=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity and diabetes are highly prevalent comorbidities in patients undergoing total hip (THA) and knee arthroplasty (TKA). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel agents that promote weight loss and glycemic control, assisting with perioperative optimization and potentially improving clinical outcomes. However, there have been safety concerns surrounding GLP-1RA use due to delayed gastric emptying and increased aspiration risk. The purpose of this systematic review was to evaluate the impact of GLP-1RA usage on perioperative outcomes following THA and TKA. METHODS: PubMed (Medline), Scopus (Embase, Medline, and Compendex), and Cochrane databases were queried to conduct a systematic review of articles from inception to June 2025. A total of 13 studies were included (119,092 hip, 227,381 knee, and 426 hip or knee). Demographics, surgical complications, medical complications, resource utilization, and revision rates were recorded at 90 days and at one and two years. Meta-analysis was performed using a random-effects model. RESULTS: The GLP-1RA use was associated with a lower risk of 90-days PJI following TKA (odds ratio (OR), 0.75; 95% confidence interval (CI), 0.57 to 1.00; P = 0.047) and a lower risk of 90-day revision following THA (OR, 0.76; 95% CI, 0.59 to 0.98; P = 0.034). There was a significant decrease in 90-day readmission rates for TKA and THA with GLP-1RA use. Of note, no significant association was found between GLP-1RA use and aspiration or pneumonia (OR, 1.09; 95% CI, 0.71 to 1.67; P = 0.70), but GLP-1RA usage was associated with an elevated risk of myocardial infarction in the setting of TKA (OR, 1.39; 95% CI, 1.05 to 1.85; P = 0.02). CONCLUSIONS: The GLP-1RA use was associated with improved early surgical outcomes and decreased resource utilization following THA and TKA. These findings suggest a potential benefit of GLP-1RA use for optimizing high-risk patients who have obesity or diabetes undergoing total joint arthroplasty.
引用
- Lee S, Singh K, Clark SC, et al. The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of 346,899 Patients. J Arthroplasty. 2025. PMID: 41072556. doi:10.1016/j.arth.2025.09.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。